Ratings Moves: ING,...
Health Care: Drugs
Biogen Idec Inc (BIIB: NASDAQ)
$234.48 1.86 | 0.80%
05/24/13 - 03:16 PM ET
Growth Rates
| GROWTH RATES |
|---|
| REVENUE (Trailing 12 Quarters) |
| EARNINGS PER SHARE (Trailing 12 Quarters) |
| DIVIDENDS (Trailing 12 Quarters) |
Portfolios with BIIB
- Portfolio NameUser Type
- User4 Overvalued Biotechs
- UserCorgies Follies
- ProNavellier & Associates
- UserMy SP portfolio
- ContributorDrugs Facing FDA Approval i...
- Contributor22 Biopharma Stocks With Br...
- UserKAREL VON ZOETE
- UserEverett Bishop Portfolio 1
- ProViking Global Investors
- ContributorTop-Rated Biotechnology Stocks
Latest BIIB Headlines from TheStreet
- The Next Big Thing In Biotech: Large-Cap Earnings
04.18.13 | 09:04 am - Biogen Idec Inc (BIIB): Today's Featured Health Care Winner 04.12.13 | 05:04 pm
- 4 Stocks Driving The Drugs Industry Higher 04.12.13 | 01:04 pm
- Biogen Idec Reaches New 52-Week High (BIIB) 04.11.13 | 10:04 am
- Biogen Idec Inc Stock Buy Recommendation Reiterated (BIIB) 04.11.13 | 10:04 am
- Biotech Multiples Are Soaring But M&A Is Dead 04.08.13 | 12:04 pm
- Biogen Idec Inc (BIIB): Today's Featured Drugs Straggler 04.05.13 | 05:04 pm
- 5 Stocks Dragging In The Health Care Sector 04.03.13 | 01:04 pm
- This Chart Explains The Biotech Bull Market 04.03.13 | 08:04 am
- Most Profitable Second Quarter Biotech Stocks 04.02.13 | 06:04 am
Press Releases for BIIB
- Image Of Biogen Idec's TECFIDERA(TM) (dimethyl Fumarate) Which Was Approved By The U.S. FDA On March 27, 2013 For Relapsing Multiple Sclerosis. (Photo: Business Wire) - Business Wire 03.27.13 | 04:03 pm
- CHMP Issues Positive Opinion For TECFIDERA™ (Dimethyl Fumarate) As A First-Line Treatment For Multiple Sclerosis In The European Union - Business Wire 03.22.13 | 08:03 am
- Positive Year One Results From Biogen Idec Phase 3 ADVANCE Trial Of PLEGRIDY™ (Peginterferon Beta-1a) Presented At AAN Meeting - Business Wire 03.20.13 | 07:03 am
- US Patent Office Grants Patent Claiming Dosing Regimen For TECFIDERA™ (Dimethyl Fumarate) - Business Wire 03.19.13 | 04:03 pm
- New TYSABRI Data Reaffirm Substantial Efficacy In Treatment Of People With MS And Demonstrate Stability Of Anti-JCV Antibody Status - Business Wire 03.18.13 | 07:03 am
- Biogen Idec To Present New Data On Diverse Neurological Portfolio At 65th AAN Annual Meeting - Business Wire 03.06.13 | 01:03 pm
- FDA Accepts Biogen Idec’s Biologics License Application For First Long-Lasting Factor IX Therapy For Hemophilia B - Business Wire 03.04.13 | 07:03 am
- Biogen Idec To Present At The Cowen And Company 33rd Annual Healthcare Conference - Business Wire 02.27.13 | 04:02 pm
- Biogen Idec To Present At The 2013 RBC Capital Markets Global Healthcare Conference - Business Wire 02.20.13 | 04:02 pm
- Biogen Idec To Present At The Citi 2013 Global Healthcare Conference - Business Wire 02.19.13 | 04:02 pm
Partner Headlines for BIIB
- Indexes Notch Sharp Declines; New 52-Week Low For Apple - Investor's Business Daily 04.17.13 | 04:04 pm
- Biotech Alkermes Poised To Swell On Pipeline Wins - Investor's Business Daily 04.16.13 | 05:04 pm
- Big Cap Leaders Slide But Show Little Technical Damage - Investor's Business Daily 04.15.13 | 07:04 pm
- Pockets of Strength In Top Groups, Few Leaders Basing - Investor's Business Daily 04.15.13 | 06:04 pm
- Sellers Smack Indexes Lower; Gold, Growth Names Slump - Investor's Business Daily 04.15.13 | 05:04 pm
- Acorda: A Biotech Company To Consider - Seeking Alpha 04.13.13 | 09:04 am
- Stocks End With Mild Losses; Nasdaq Rises 2.8% For Week - Investor's Business Daily 04.12.13 | 05:04 pm
- Stocks Lift Off Session Lows; Proto Labs Tumbles - Investor's Business Daily 04.12.13 | 01:04 pm
- Stocks Slip In Mixed Trade; Sinclair Broadcast Hits New High - Investor's Business Daily 04.12.13 | 11:04 am
- Benzinga's Top Pre-Market Gainers - Benzinga 04.12.13 | 09:04 am
